Investigational drug · Phase 2
ND0612
Also called: ND0612H
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Parkinson's Disease.
Phase 2Last checked: Nov 19, 2026Latest source record: May 30, 2025 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
9
Any phase or sponsor naming "ND0612"
First trial start
2016
May 4, 2016
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "ND0612", any sponsor or status.
Conditions studied
As listed on its trial records.
- Parkinson's Disease
Approved drugs for the same conditions: Parkinson's disease · Neurology
Largest trials
Live from ClinicalTrials.gov: studies naming "ND0612" as an intervention, largest first.
- Efficacy, Safety and Tolerability Study of ND0612 vs. Oral Immediate Release Levodopa/Carbidopa (IR-LD/CD) in Subjects With Parkinson's Disease Experiencing Motor FluctuationsPivotal-lookingActive, not recruiting
NeuroDerm Ltd.Industry
NCT04006210 · 381 participants · Start Sep 30, 2019 · Primary completion Nov 1, 2022
Drug: Oral IR-LD/CD; Placebo for Oral IR-LD/CD · For: Parkinson's Disease
Sites: Phoenix, Arizona; Little Rock, Arkansas; Los Angeles, California · 103 sites in all
- A Long Term Safety Study of ND0612 Administered as a Continuous SC Infusion in Advanced Parkinson's DiseaseActive, not recruiting
NeuroDerm Ltd.Industry
NCT02726386 · 214 participants · Start May 4, 2016 · Primary completion Sep 9, 2019
Drug: ND0612 · For: Parkinson's Disease
Sites: Phoenix, Arizona; Little Rock, Arkansas; Fountain Valley, California · 57 sites in all
NeuroDerm Ltd.Industry
NCT02577523 · 38 participants · Start Dec 29, 2015 · Primary completion Dec 20, 2016
Drug: ND0612 (Levodopa/Carbidopa solution); ND0612 (Levodopa/Carbidopa solution) + morning oral IR-LD/CD · For: Parkinson's Disease
Sites: Chicago, Illinois; Farmington Hills, Michigan; Cincinnati, Ohio · 11 sites in all
NeuroDerm Ltd.Industry
NCT02604914 · 36 participants · Start May 29, 2015 · Primary completion Jun 30, 2016
Drug: ND0612; LCIG · For: Parkinson's Disease
Sites: Ruddington, United Kingdom
NeuroDerm Ltd.Industry
NCT01486628 · 36 participants · Start Apr 30, 2012 · Primary completion Nov 22, 2012
Drug: ND0612; Placebo · For: Parkinson's Disease
Sites: Jerusalem, Israel
NeuroDerm Ltd.Industry
NCT01883505 · 30 participants · Start Jan 6, 2014 · Primary completion Apr 26, 2015
Drug: ND0612; Placebo and 1 more · For: Parkinson's Disease
Sites: Jerusalem, Israel; Petah Tikva, Israel; Tel Aviv, Israel
NeuroDerm Ltd.Industry
NCT02096601 · 16 participants · Start Aug 11, 2014 · Primary completion Mar 15, 2015
Drug: LD/CD SC solution; Entacapone · For: Parkinson's Disease
Sites: Jerusalem, Israel; Tel Aviv, Israel
NeuroDerm Ltd.Industry
NCT01725802 · 8 participants · Start Dec 16, 2012 · Primary completion Feb 26, 2013
Drug: Levodopa/carbidopa solution for SC administration; Placebo · For: Parkinson's Disease
Sites: Jerusalem, Israel
NeuroDerm Ltd.Industry
NCT02782481 · 0 participants · Start Aug 2016 · Primary completion Oct 15, 2018
Drug: ND0612; Placebo · For: Parkinson's Disease
Sites: Jerusalem, Israel
Newest research
PubMed records naming it or its code names, newest first.
- Recent Developments in the Drug Treatment of Parkinson's Disease.
Leiter S, Mahlknecht P, Poewe W · Drugs 2026
- Continuous subcutaneous levodopa and foslevodopa infusion therapy for motor symptoms of Parkinson disease: A systematic review of observational studies.
Ali A, Cheema WA, Shamoon M, et al. · Medicine (Baltimore) 2026
- Transition from subcutaneous levodopa/carbidopa (ND0612) to Foslevodopa/Foscarbidopa in advanced Parkinson's disease.
De Rosa MA, Calisi D, Russo M, et al. · Clin Park Relat Disord 2026
- Subcutaneous Levodopa in Parkinson's Disease: A Systematic Review and Meta-Analysis.
Burton M, Marsden D, Harish D, et al. · Eur J Neurol 2026
- Infusion therapies for advanced Parkinson's disease: current evidence and practical challenges - a narrative review.
Toś M, Dymek A, Siuda J · Neurol Neurochir Pol 2026
- Efficacy and safety of continuous subcutaneous ND0612 Infusion compared to oral and alternative regimens in managing motor fluctuations in Parkinson's disease: a systematic review and meta-analysis.
Abunamoos A, Alghaniem MMA, Qtaishat FA, et al. · Neurol Sci 2025
Also in development for Parkinson's Disease
- PrasinezumabRO7046015, PRX002Phase 33 trials
Roche (Genentech) · Parkinson's Disease, Parkinsons Disease
- CVN424Phase 32 trials
Cerevance · Parkinson Disease, Parkinson's Disease
- GM1Phase 32 trials
Qilu Pharmaceutical Co., Ltd. · Chemotherapy-induced Peripheral Neuropathy (CIPN), Parkinson's Disease
- iPSChuman allogeneic induced pluripotent stem cell -derived dopaminergic neural progenitor cell, Allogeneic Human Induced Pluripotent Stem Cell -Derived Motor Neuron Progenitor CellsPhase 23 trials
XellSmart Bio-Pharmaceutical (Suzhou) Co., Ltd. · Spinal Cord Injury, Safety, Efficacy
- RO7568282Phase 22 trials
Roche (Genentech) · Parkinson's Disease, Alzheimer's Disease
- BIA 28-6156Phase 21 trial
Bial R&D Investments, S.A. · Parkinson's Disease
- MT101-5Phase 21 trial
Mthera Pharma Co., Ltd. · Parkinson's Disease
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.